Aligos Therapeutics Inc. Common Stock (ALGS)
Stock · NASDAQ · Health Care
$4.99as of 10/16/2026
Price chart
Active signals
ALGS Signal Track Record
How signals performed across all stocks →What ALGS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 25 | -1.7% | 48% | September 21, 2026 |
| Bollinger Band BreakdownActive now | 25 | -3.3% | 44% | September 9, 2026 |
| Bollinger Band Breakout | 18 | -2.6% | 33% | August 10, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -20.2% | 13% | April 13, 2026 |
| Any 20-session window (baseline) | -5.3% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsi…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 82
- Website
- www.aligos.com/
Fundamentals
- 1-day range
- $4.86$5.5
- Market cap
- $34.10M
- P/E (trailing)
- —
- P/E (forward)
- -0.93
- EPS (trailing)
- $-7.31
- Dividend yield
- —
- Beta
- 2.48
- Avg. volume
- 84.3K
How Aligos Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Aligos Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALGSAligos Therapeutics Inc. Common Stock$4.86▼ 9.83%Market cap $34.10MP/E —$3.98$13.69
- ENGNWenGene Therapeutics Inc. Warrants$0.17▲ 1.19%Market cap $33.75MP/E —$0.1113$4.2
- ESLAEstrella Immunopharma Inc. Common Stock$0.43▼ 19.63%Market cap $32.10MP/E —$0.295$3.15
- DYAIDyadic International Inc. Common Stock$0.41▼ 2.38%Market cap $37.17MP/E —$0.3401$1.6
- QNCXQuince Therapeutics Inc. Common Stock$32.03▼ 3.61%Market cap $30.04MP/E —$15.1$910
- ELUTElutia Inc. Class A Common Stock$0.794▲ 0.63%Market cap $38.95MP/E 0.67$0.5$1.39
- CVMCel-Sci Corporation Common Stock$1.79▲ 2.87%Market cap $28.14MP/E —$0.89$10.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALGS Aligos Therapeutics Inc. Common Stock | $34.10M | — | $4.86 | ▼ 9.83% | $3.98$13.69 |
| ENGNW enGene Therapeutics Inc. Warrants | $33.75M | — | $0.17 | ▲ 1.19% | $0.1113$4.2 |
| ESLA Estrella Immunopharma Inc. Common Stock | $32.10M | — | $0.43 | ▼ 19.63% | $0.295$3.15 |
| DYAI Dyadic International Inc. Common Stock | $37.17M | — | $0.41 | ▼ 2.38% | $0.3401$1.6 |
| QNCX Quince Therapeutics Inc. Common Stock | $30.04M | — | $32.03 | ▼ 3.61% | $15.1$910 |
| ELUT Elutia Inc. Class A Common Stock | $38.95M | 0.67 | $0.794 | ▲ 0.63% | $0.5$1.39 |
| CVM Cel-Sci Corporation Common Stock | $28.14M | — | $1.79 | ▲ 2.87% | $0.89$10.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Aligos Therapeutics Announces Acceptance Of Five Abstracts At American Association For Study Of Liver Disease's The Liver Meetingbenzinga · 10/5/2026
- Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026Yahoo · 10/5/2026
- Aligos Therapeutics Announces Acceptance Of Five Abstracts At American Association For Study Of Liver Disease's The Liver MeetingBenzinga · 10/5/2026
- Discover the top movers in Monday's pre-market session.ChartMill · 9/21/2026
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · 9/21/2026
- Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · 9/21/2026
- Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving PremarketBenzinga · 9/21/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 2.75M
- Total value held
- $20.40M
- Institutional holders
- 31
- Unknown444.1K
- Unknown412.0K
- Unknown327.2K
- Unknown267.1K
- Unknown229.8K
- Unknown178.3K
- Unknown177.4K
- Unknown148.8K
- Unknown100.5K
- Unknown83.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aligos Therapeutics Presents Five Abstracts at Liver Meeting 2026
Aligos Therapeutics announced that five of its research abstracts were accepted for presentation at The Liver Meeting 2026. This event highlights the company's ongoing scientific work in liver disease. The news provides context for the stock's current trading range, which remains well below the average analyst price target.
Aligos Therapeutics Presents Five Abstracts at Liver Meeting 2026. Aligos Therapeutics announced that five of its research abstracts were accepted for presentation at The Liver Meeting 2026. This event highlights the company's ongoing scientific work in liver disease. The news provides context for the stock's current trading range, which remains well below the average analyst price target.